Haval Shirwan - Publications

Affiliations: 
University of Louisville, Louisville, KY, United States 
Area:
Immunology, Biochemistry, Molecular Biology

68 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Coronel MM, Martin KE, Hunckler MD, Barber G, O'Neill EB, Medina JD, Opri E, McClain CA, Batra L, Weaver JD, Lim HS, Qiu P, Botchwey EA, Yolcu ES, Shirwan H, et al. Immunotherapy via PD-L1-presenting biomaterials leads to long-term islet graft survival. Science Advances. 6: eaba5573. PMID 32923626 DOI: 10.1126/Sciadv.Aba5573  0.4
2020 Shrestha P, Batra L, Tariq Malik M, Tan M, Yolcu ES, Shirwan H. Immune checkpoint CD47 molecule engineered islets mitigate instant blood-mediated inflammatory reaction and show improved engraftment following intraportal transplantation. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. PMID 32342638 DOI: 10.1111/Ajt.15958  0.4
2020 Batra L, Shrestha P, Zhao H, Woodward KB, Togay A, Tan M, Grimany-Nuno O, Malik MT, Coronel MM, García AJ, Shirwan H, Yolcu ES. Localized Immunomodulation with PD-L1 Results in Sustained Survival and Function of Allogeneic Islets without Chronic Immunosuppression. Journal of Immunology (Baltimore, Md. : 1950). PMID 32253240 DOI: 10.4049/Jimmunol.2000055  0.4
2020 Shirwan H, Batra L, Malik MT, Shrestha P, Hawthorne JL, Yolcu ES. Abstract 4516: SA-4-1BBL as a novel agonist of CD137 has immunoprevention efficacy against various tumor types Immunology. 80: 4516-4516. DOI: 10.1158/1538-7445.Am2020-4516  0.4
2020 Batra L, Shrestha P, Zhao H, Woodward KB, Togay A, Tan M, Grimany-Nuno O, Malik MT, Coronel MM, García AJ, Shirwan H, Yolcu E. Immunomodulation With Sa-Pdl1 Protein On Pancreatic Islets Promotes Indefinite Graft Survival In Allogeneic Recipients Transplantation. 104. DOI: 10.1097/01.Tp.0000699084.35417.96  0.32
2019 Woodward KB, Zhao H, Shrestha P, Batra L, Tan M, Grimany-Nuno O, Bandura-Morgan L, Askenasy N, Shirwan H, Yolcu ES. Pancreatic islets engineered with a FasL protein induce systemic tolerance at the induction phase that evolves into long-term graft-localized immune privilege. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. PMID 31850658 DOI: 10.1111/Ajt.15747  0.4
2019 Yerneni SS, Lathwal S, Shrestha P, Shirwan H, Matyjaszewski K, Weiss L, Yolcu ES, Campbell PG, Das SR. Rapid On-Demand Extracellular Vesicle Augmentation with Versatile Oligonucleotide Tethers. Acs Nano. PMID 31436946 DOI: 10.1021/Acsnano.9B04651  0.4
2019 Bowen W, Batra L, Pulsifer AR, Yolcu ES, Lawrenz MB, Shirwan H. Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague. Vaccine. PMID 31416643 DOI: 10.1016/J.Vaccine.2019.07.103  0.4
2019 Barsoumian HB, Batra L, Shrestha P, Bowen WS, Zhao H, Egilmez NK, Gomez-Gutierrez JG, Yolcu ES, Shirwan H. A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4 T and Natural Killer Cells. Cancer Research. 79: 783-794. PMID 30770367 DOI: 10.1158/0008-5472.Can-18-2401  0.4
2019 Shirwan H, Barsoumian HB, Batra L, Shrestha P, Bowen WS, Zhao H, Egilmez NK, Gomez-Gutierrez JG, Yolcu ES. Abstract 4145: A novel form of 4-1BB agonist shows robust immune protection against various tumor types through CD4+memory-like T and NK cell axis Cancer Research. 79: 4145-4145. DOI: 10.1158/1538-7445.Sabcs18-4145  0.4
2018 Skoumal M, Woodward KB, Zhao H, Wang F, Yolcu ES, Pearson RM, Hughes KR, García AJ, Shea LD, Shirwan H. Localized immune tolerance from FasL-functionalized PLG scaffolds. Biomaterials. 192: 271-281. PMID 30458362 DOI: 10.1016/J.Biomaterials.2018.11.015  0.4
2018 Headen DM, Woodward KB, Coronel MM, Shrestha P, Weaver JD, Zhao H, Tan M, Hunckler MD, Bowen WS, Johnson CT, Shea L, Yolcu ES, García AJ, Shirwan H. Local immunomodulation with Fas ligand-engineered biomaterials achieves allogeneic islet graft acceptance. Nature Materials. PMID 29867165 DOI: 10.1038/S41563-018-0099-0  0.4
2017 Yolcu ES, Shirwan H, Askenasy N. Fas/Fas-Ligand Interaction As a Mechanism of Immune Homeostasis and β-Cell Cytotoxicity: Enforcement Rather Than Neutralization for Treatment of Type 1 Diabetes. Frontiers in Immunology. 8: 342. PMID 28396667 DOI: 10.3389/Fimmu.2017.00342  0.4
2017 Yolcu ES, Shirwan H, Askenasy N. Mechanisms of Tolerance Induction by Hematopoietic Chimerism: The Immune Perspective. Stem Cells Translational Medicine. PMID 28186688 DOI: 10.1002/Sctm.16-0358  0.4
2016 Barsoumian HB, Yolcu ES, Shirwan H. 4-1BB Signaling in Conventional T Cells Drives IL-2 Production That Overcomes CD4+CD25+FoxP3+ T Regulatory Cell Suppression. Plos One. 11: e0153088. PMID 27049955 DOI: 10.1371/Journal.Pone.0153088  0.4
2016 Srivastava AK, Yolcu ES, Dinc G, Sharma RK, Shirwan H. SA-4-1BBL/MPL as a novel immune adjuvant platform to combat cancer. Oncoimmunology. 5: e1064580. PMID 26942082 DOI: 10.1080/2162402X.2015.1064580  0.4
2015 Woodward KB, Wang F, Zhao H, Yolcu ES, Shirwan H. Novel technologies to engineer graft for tolerance induction. Current Opinion in Organ Transplantation. PMID 26626421 DOI: 10.1097/Mot.0000000000000270  0.4
2014 Srivastava AK, Dinc G, Sharma RK, Yolcu ES, Zhao H, Shirwan H. SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines. Cancer Research. 74: 6441-51. PMID 25252915 DOI: 10.1158/0008-5472.Can-14-1768-A  0.4
2014 Dinc G, Pennington JM, Yolcu ES, Lawrenz MB, Shirwan H. Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant. Vaccine. 32: 5035-40. PMID 25045812 DOI: 10.1016/J.Vaccine.2014.07.015  0.4
2014 Shirwan H, Yolcu ES, Sharma RK, Zaho H, Grimany-Nuno O. The direct display of costimulatory proteins on tumor cells as a means of vaccination for cancer immunotherapy. Methods in Molecular Biology (Clifton, N.J.). 1139: 269-85. PMID 24619687 DOI: 10.1007/978-1-4939-0345-0_23  0.4
2014 Sharma RK, Yolcu ES, Shirwan H. SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines. Expert Review of Vaccines. 13: 387-98. PMID 24521311 DOI: 10.1586/14760584.2014.880340  0.4
2014 Hakim F, Wang Y, Zhang SX, Zheng J, Yolcu ES, Carreras A, Khalyfa A, Shirwan H, Almendros I, Gozal D. Fragmented sleep accelerates tumor growth and progression through recruitment of tumor-associated macrophages and TLR4 signaling. Cancer Research. 74: 1329-37. PMID 24448240 DOI: 10.1158/0008-5472.Can-13-3014  0.4
2013 Sharma RK, Yolcu ES, Srivastava AK, Shirwan H. CD4+ T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models. Plos One. 8: e73145. PMID 24066030 DOI: 10.1371/Journal.Pone.0073145  0.4
2013 Yolcu ES, Kaminitz A, Mizrahi K, Ash S, Yaniv I, Stein J, Shirwan H, Askenasy N. Immunomodulation with donor regulatory T cells armed with Fas-ligand alleviates graft-versus-host disease. Experimental Hematology. 41: 903-11. PMID 23743300 DOI: 10.1016/J.Exphem.2013.04.016  0.4
2013 Shirwan H, Sharma RK, Srivastava AK, Yolcu ES. Co-stimulatory tumor necrosis factor ligands as adjuvants for the development of subunit-based anticancer vaccines. Oncoimmunology. 2: e23440. PMID 23734306 DOI: 10.4161/Onci.23440  0.4
2013 Kaminitz A, Yolcu ES, Mizrahi K, Shirwan H, Askenasy N. Killer Treg cells ameliorate inflammatory insulitis in non-obese diabetic mice through local and systemic immunomodulation. International Immunology. 25: 485-94. PMID 23657001 DOI: 10.1093/Intimm/Dxt016  0.4
2012 Srivastava AK, Sharma RK, Yolcu ES, Ulker V, MacLeod K, Dinc G, Shirwan H. Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner. Plos One. 7: e48463. PMID 23144888 DOI: 10.1371/Journal.Pone.0048463  0.4
2012 Madireddi S, Schabowsky RH, Srivastava AK, Sharma RK, Yolcu ES, Shirwan H. SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ. Plos One. 7: e42459. PMID 22870329 DOI: 10.1371/Journal.Pone.0042459  0.4
2011 Yolcu ES, Zhao H, Bandura-Morgan L, Lacelle C, Woodward KB, Askenasy N, Shirwan H. Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice. Journal of Immunology (Baltimore, Md. : 1950). 187: 5901-9. PMID 22068235 DOI: 10.4049/Jimmunol.1003266  0.4
2011 Kaminitz A, Yolcu ES, Askenasy EM, Stein J, Yaniv I, Shirwan H, Askenasy N. Effector and naturally occurring regulatory T cells display no abnormalities in activation induced cell death in NOD mice. Plos One. 6: e21630. PMID 21738739 DOI: 10.1371/Journal.Pone.0021630  0.4
2011 Kaminitz A, Yolcu ES, Stein J, Yaniv I, Shirwan H, Askenasy N. Killer Treg restore immune homeostasis and suppress autoimmune diabetes in prediabetic NOD mice. Journal of Autoimmunity. 37: 39-47. PMID 21497486 DOI: 10.1016/J.Jaut.2011.03.003  0.4
2011 Srivastava A, Sharma R, Zhao H, Yolcu E, Shirwan H. Abstract 765: Costimulatory SA-4-1BBL and monophosphoryl lipid A as novel adjuvant system for the development of cancer vaccines with robust therapeutic efficacy Cancer Research. 71: 765-765. DOI: 10.1158/1538-7445.Am2011-765  0.32
2010 Gu X, Yang J, Zhao H, Yolcu ES, Shirwan H. [Allograft tolerance induced by FasL chimeric protein decorated donor splenocytes]. Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]. 48: 702-5. PMID 20646556 DOI: 10.3760/Cma.J.Issn.0529-5815.2010.09.015  0.4
2010 Sharma RK, Srivastava AK, Yolcu ES, MacLeod KJ, Schabowsky RH, Madireddi S, Shirwan H. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model. Vaccine. 28: 5794-802. PMID 20603135 DOI: 10.1016/J.Vaccine.2010.06.073  0.4
2010 Sharma RK, Yolcu ES, Elpek KG, Shirwan H. Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy. Cancer Gene Therapy. 17: 730-41. PMID 20559332 DOI: 10.1038/Cgt.2010.29  0.4
2010 Pearl-Yafe M, Mizrahi K, Stein J, Yolcu ES, Kaplan O, Shirwan H, Yaniv I, Askenasy N. Tumor necrosis factor receptors support murine hematopoietic progenitor function in the early stages of engraftment. Stem Cells (Dayton, Ohio). 28: 1270-80. PMID 20506490 DOI: 10.1002/Stem.448  0.4
2010 Sharma RK, Schabowsky RH, Srivastava AK, Elpek KG, Madireddi S, Zhao H, Zhong Z, Miller RW, Macleod KJ, Yolcu ES, Shirwan H. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Cancer Research. 70: 3945-54. PMID 20406989 DOI: 10.1158/0008-5472.Can-09-4480  0.4
2010 Sharma RK, Schabowsky R, Srivastava AK, Yolcu ES, Elpek KG, Zhao H, Madireddi S, Shirwan H. Abstract 2416: SA-4-1BBL costimulatory ligand as an immune modulator and effective vehicle to deliver antigens into dendritic cells for the generation of robust therapeutic antitumor immune responses Cancer Research. 70: 2416-2416. DOI: 10.1158/1538-7445.Am10-2416  0.4
2010 Sharma RK, Yolcu ES, Elpek KG, Shirwan H. Abstract 1501: Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy Cancer Research. 70: 1501-1501. DOI: 10.1158/1538-7445.Am10-1501  0.4
2009 Schabowsky RH, Elpek KG, Madireddi S, Sharma RK, Yolcu ES, Bandura-Morgan L, Miller R, MacLeod KJ, Mittler RS, Shirwan H. A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity. Vaccine. 28: 512-22. PMID 19836479 DOI: 10.1016/J.Vaccine.2009.09.127  0.4
2009 Schabowsky RH, Sharma RK, Madireddi S, Srivastava A, Yolcu ES, Shirwan H. ProtEx technology for the generation of novel therapeutic cancer vaccines. Experimental and Molecular Pathology. 86: 198-207. PMID 19454266 DOI: 10.1016/J.Yexmp.2009.01.010  0.4
2009 Sharma RK, Elpek KG, Yolcu ES, Schabowsky RH, Zhao H, Bandura-Morgan L, Shirwan H. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Research. 69: 4319-26. PMID 19435920 DOI: 10.1158/0008-5472.Can-08-3141  0.4
2008 Yolcu ES, Gu X, Lacelle C, Zhao H, Bandura-Morgan L, Askenasy N, Shirwan H. Induction of tolerance to cardiac allografts using donor splenocytes engineered to display on their surface an exogenous fas ligand protein. Journal of Immunology (Baltimore, Md. : 1950). 181: 931-9. PMID 18606644 DOI: 10.4049/Jimmunol.181.2.931  0.4
2007 Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Current Opinion in Investigational Drugs (London, England : 2000). 8: 1002-8. PMID 18058571  0.4
2007 Elpek KG, Yolcu ES, Franke DD, Lacelle C, Schabowsky RH, Shirwan H. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. Journal of Immunology (Baltimore, Md. : 1950). 179: 7295-304. PMID 18025172 DOI: 10.4049/Jimmunol.179.11.7295  0.4
2007 Pearl-Yafe M, Yolcu ES, Stein J, Kaplan O, Shirwan H, Yaniv I, Askenasy N. Expression of Fas and Fas-ligand in donor hematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis. Experimental Hematology. 35: 1601-12. PMID 17889725 DOI: 10.1016/J.Exphem.2007.07.010  0.4
2007 Pearl-Yafe M, Stein J, Yolcu ES, Farkas DL, Shirwan H, Yaniv I, Askenasy N. Fas transduces dual apoptotic and trophic signals in hematopoietic progenitors. Stem Cells (Dayton, Ohio). 25: 3194-203. PMID 17872500 DOI: 10.1634/Stemcells.2007-0402  0.4
2007 Elpek KG, Lacelle C, Singh NP, Yolcu ES, Shirwan H. CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. Journal of Immunology (Baltimore, Md. : 1950). 178: 6840-8. PMID 17513732 DOI: 10.4049/Jimmunol.178.11.6840  0.4
2007 Pearl-Yafe M, Yolcu ES, Stein J, Kaplan O, Yaniv I, Shirwan H, Askenasy N. Fas ligand enhances hematopoietic cell engraftment through abrogation of alloimmune responses and nonimmunogenic interactions. Stem Cells (Dayton, Ohio). 25: 1448-55. PMID 17363551 DOI: 10.1634/Stemcells.2007-0013  0.4
2007 Franke DD, Yolcu ES, Alard P, Kosiewicz MM, Shirwan H. A novel multimeric form of FasL modulates the ability of diabetogenic T cells to mediate type 1 diabetes in an adoptive transfer model. Molecular Immunology. 44: 2884-92. PMID 17324464 DOI: 10.1016/J.Molimm.2007.01.014  1
2007 Gomez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, Shirwan H, Sam Zhou H, McMasters KM. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunology, Immunotherapy : Cii. 56: 997-1007. PMID 17146630 DOI: 10.1007/S00262-006-0247-2  0.4
2006 Singh NP, Miller RW, Yolcu ES, Kilinc MO, Oechsli M, Huseby R, Taylor DD, Perry MT, Larocca RV, Shirwan H. Primary tumor cells resected from cancer patients and decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for the induction of autologous T cell immune responses ex vivo. Human Gene Therapy. 17: 334-46. PMID 16544982 DOI: 10.1089/Hum.2006.17.334  0.4
2006 Kilinc MO, Mukundan L, Yolcu ES, Singh NP, Suttles J, Shirwan H. Generation of a multimeric form of CD40L with potent immunostimulatory activity using streptavidin as a chaperon. Experimental and Molecular Pathology. 80: 252-61. PMID 16487512 DOI: 10.1016/J.Yexmp.2005.12.004  0.4
2006 Pearl-Yafe M, Yolcu ES, Yaniv I, Stein J, Shirwan H, Askenasy N. The dual role of Fas-ligand as an injury effector and defense strategy in diabetes and islet transplantation. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 28: 211-22. PMID 16435302 DOI: 10.1002/Bies.20356  0.4
2006 Franke DD, Shirwan H. Prophylactic fenbendazole therapy does not affect the incidence and onset of type 1 diabetes in non-obese diabetic mice. International Immunology. 18: 453-8. PMID 16415097 DOI: 10.1093/Intimm/Dxh385  1
2005 Singh NP, Yolcu ES, Askenasy N, Shirwan H. ProtEx: a novel technology to display exogenous proteins on the cell surface for immunomodulation. Annals of the New York Academy of Sciences. 1056: 344-58. PMID 16387700 DOI: 10.1196/Annals.1352.036  0.4
2005 Köksoy S, Elpek KG, Yolcu ES, Shirwan H. Tolerance to rat heart grafts induced by intrathymic immunomodulation is mediated by indirect recognition primed CD4+CD25+ Treg cells. Transplantation. 79: 1492-7. PMID 15940037 DOI: 10.1097/01.Tp.0000159870.01567.02  0.4
2005 Askenasy N, Yolcu ES, Yaniv I, Shirwan H. Induction of tolerance using Fas ligand: a double-edged immunomodulator. Blood. 105: 1396-404. PMID 15486063 DOI: 10.1182/Blood-2004-06-2364  0.4
2004 Singh N, Yolcu ES, Miller RW, Shirwan H, Huseby RM, Kilinc O, Taylor D, Oechsli M, Larocca R. Primary tumor cells from cancer patients "decorated" with a novel form of CD80 protein effectively induce autologous T-cell responses ex-vivo. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2580. PMID 28015279 DOI: 10.1200/jco.2004.22.14_suppl.2580  0.4
2004 Köksoy S, Kakoulidis TP, Shirwan H. Chronic heart allograft rejection in rats demonstrates a dynamic interplay between IFN-gamma and IL-10 producing T cells. Transplant Immunology. 13: 201-9. PMID 15381203 DOI: 10.1016/J.Trim.2004.03.001  0.32
2003 Askenasy N, Yolcu ES, Shirwan H, Stein J, Yaniv I, Farkas DL. Characterization of adhesion and viability of early seeding hematopoietic cells in the host bone marrow in vivo and in situ. Experimental Hematology. 31: 1292-300. PMID 14662337 DOI: 10.1016/J.Exphem.2003.09.006  0.4
2003 Singh NP, Yolcu ES, Taylor DD, Gercel-Taylor C, Metzinger DS, Dreisbach SK, Shirwan H. A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity. Cancer Research. 63: 4067-73. PMID 12874008  0.4
2003 Shirwan H, Mhoyan A, Yolcu ES, Que X, Ibrahim S. Chronic cardiac allograft rejection in a rat model disparate for one single class I MHC molecule is associated with indirect recognition by CD4(+) T cells. Transplant Immunology. 11: 179-85. PMID 12799202 DOI: 10.1016/S0966-3274(03)00004-2  0.4
2003 Shirwan H, Mhoyan A, Kakoulidis TP, Yolcu ES, Ibrahim S. Prevention of chronic rejection with immunoregulatory cells induced by intrathymic immune modulation with class I allopeptides. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 3: 581-9. PMID 12752314 DOI: 10.1034/J.1600-6143.2003.00052.X  0.4
2003 Mhoyan A, Wu GD, Kakoulidis TP, Que X, Yolcu ES, Cramer DV, Shirwan H. Predominant expression of the Th2 response in chronic cardiac allograft rejection. Transplant International : Official Journal of the European Society For Organ Transplantation. 16: 464-73. PMID 12712237 DOI: 10.1007/S00147-003-0590-6  0.4
2003 Askenasy N, Yolcu ES, Wang Z, Shirwan H. Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection. Circulation. 107: 1525-31. PMID 12654611 DOI: 10.1161/01.Cir.0000064893.96179.7E  0.4
2003 Askenasy N, Yolcu ES, Shirwan H, Wang Z, Farkas DL, Yoleuk ES. Cardiac allograft acceptance after localized bone marrow transplantation by isolated limb perfusion in nonmyeloablated recipients. Stem Cells (Dayton, Ohio). 21: 200-7. PMID 12634416 DOI: 10.1634/Stemcells.21-2-200  0.4
2002 Yolcu ES, Askenasy N, Singh NP, Cherradi SE, Shirwan H. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity. 17: 795-808. PMID 12479825 DOI: 10.1016/S1074-7613(02)00482-X  0.4
Show low-probability matches.